About Squalene synthase
Squalene synthase (FDFT1) is a protein
from Homo sapiens identified by UniProt accession
P37268, 417 residues long.
MolForge cross-references it against 0 known binders and
169 disease associations.
Target properties
| Protein name | Squalene synthase |
| UniProt accession | P37268 |
| Gene | FDFT1 |
| Organism | Homo sapiens |
| Length | 417 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (169)
Diseases linked to this target (Open Targets).
- squalene synthase deficiency · score 0.51
- Hypercholesterolemia · score 0.40
- reticulocyte count · score 0.35
- C-reactive protein measurement · score 0.34
- Disorder of lipid metabolism · score 0.32
- mean corpuscular volume · score 0.32
- blood protein measurement · score 0.29
- reticulocyte measurement · score 0.29
- triglyceride measurement · score 0.29
- mean reticulocyte volume · score 0.29
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P37268-F1 | alphafold | PREDICTED | 89.14 | — |
Amino-acid sequence (417 residues)
MEFVKCLGHP EEFYNLVRFR IGGKRKVMPK MDQDSLSSSL KTCYKYLNQT SRSFAAVIQA LDGEMRNAVC IFYLVLRALD TLEDDMTISV EKKVPLLHNF HSFLYQPDWR FMESKEKDRQ VLEDFPTISL EFRNLAEKYQ TVIADICRRM GIGMAEFLDK HVTSEQEWDK YCHYVAGLVG IGLSRLFSAS EFEDPLVGED TERANSMGLF LQKTNIIRDY LEDQQGGREF WPQEVWSRYV KKLGDFAKPE NIDLAVQCLN ELITNALHHI PDVITYLSRL RNQSVFNFCA IPQVMAIATL AACYNNQQVF KGAVKIRKGQ AVTLMMDATN MPAVKAIIYQ YMEEIYHRIP DSDPSSSKTR QIISTIRTQN LPNCQLISRS HYSPIYLSFV MLLAALSWQY LTTLSQVTED YVQTGEH
Explore Squalene synthase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets